GHRH Antagonists Effectively Suppress Triple-Negative Breast Cancer Growth In Vivo
Background
Triple-negative breast cancer (TNBC) is an exceptionally aggressive and challenging form of breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors. This lack of common therapeutic targets means that standard hormone therapies and HER2-targeted drugs are ineffective, leaving chemotherapy as the primary, often insufficient, treatment option. Patients with TNBC face higher recurrence rates and poorer prognoses, highlighting an urgent need for novel and more effective therapeutic strategies. This study addresses the critical knowledge gap by exploring growth hormone-releasing hormone (GHRH) antagonists as a potential new treatment pathway for TNBC.
Results
Treatment with GHRH antagonists significantly inhibited tumor growth and reduced tumor burden in the TNBC mouse model. The high-dose group (20 µg/day MZ-4-71) exhibited a remarkable 68% reduction in tumor volume compared to the vehicle control group (p<0.001), while the lower-dose group (10 µg/day) achieved a substantial 45% reduction (p<0.01). The most compelling finding was a 78% decrease in final tumor weight in mice treated with 20 µg/day MZ-4-71 compared to vehicle-treated controls (p<0.001), demonstrating potent anti-tumor efficacy. Immunohistochemical analysis of excised tumors revealed a 55% decrease in the proliferation marker Ki-67 and a 35% reduction in VEGF (Vascular Endothelial Growth Factor, a protein that promotes new blood vessel growth) in the high-dose treatment group. Furthermore, gene expression profiling showed a 3.1-fold downregulation of IGF-1R (Insulin-like Growth Factor 1 Receptor) and a 2.7-fold decrease in EGFR (Epidermal Growth Factor Receptor) expression, indicating broad anti-proliferative and anti-angiogenic effects.
Why It Matters
This study provides robust evidence that GHRH antagonists represent a promising novel therapeutic strategy for triple-negative breast cancer, a disease with significant unmet medical needs. By demonstrating significant tumor growth suppression and modulation of key oncogenic pathways like IGF-1R and EGFR, these findings suggest a multi-faceted mechanism of action. The successful inhibition of TNBC in vivo paves the way for potential clinical development of GHRH antagonists as a new, targeted treatment option for patients. Future research should focus on comprehensive toxicology profiles, optimizing dosing regimens, and ultimately progressing to Phase I and II human clinical trials to evaluate safety and efficacy in patients.